WCG Biosafety Expert Dr. David Emery to Discuss Biosafety Considerations with Human Gene Transfer at 57th Annual American Biological Safety Association Conference

PRINCETON, N.J., Oct. 2, 2014 – WIRB-Copernicus Group (WCG), the world’s largest provider of regulatory and ethical review services for clinical research, announced today that WCG BiosafetyTM expert, David W. Emery, Ph.D., will be presenting an educational preconference session in conjunction with the 57th Annual American Biological Safety Association (ABSA) Conference being held Oct. 3-8 in San Diego, CA.

Dr. Emery will host a workshop entitled: “Biosafety Considerations with Human Gene Transfer” from 8:00 a.m. to noon PDT on Friday, Oct. 3. His presentation will include an overview of the current scope of human gene transfer research, an in-depth review of the most common vector systems used for clinical gene transfer, and a critical exposition of the current regulatory environment surrounding the field. He will also provide meeting attendees with practical suggestions for how to approach risk assessment for human gene transfer clinical trials, which will include specific examples and practicums.

“As the gene therapy field matures, it is becoming increasingly important that biosafety professionals are trained in the clinical implications of the underlying technologies,” said Dr. Emery. “Issues such as potential side effects, viral shedding, and the changing regulatory environment will need to be considered as part of an appropriate review of these clinical studies. This workshop is designed to assist biosafety professionals in carrying out these assessments.”

Serving as Biosafety Manager for the company’s WCG Biosafety division, Dr. Emery brings more than 30 years’ experience to the field of genetic engineering and gene therapy research. He has been actively engaged in the American Society of Gene and Cell Therapy for 17 years. Previously, Dr. Emery was the primary reviewer of clinical gene transfer studies for the University of Washington Institutional Biosafety Committee (IBC) for more than 15 years, and he served as the chair of that institution’s IBC for 11 years.

For more information about this year’s ABSA conference, please visit: http://absaconference.org.


About The WIRB-­‐Copernicus Group
The WIRB-Copernicus Group (WCG) is the world’s largest and most trusted provider of regulatory and ethical review services for human research. The pioneer of independent ethical review, WCG continues to drive ingenuity in the clinical research space. Today, WCG’s solutions are built upon the foundation of ethical review, but have grown to include a suite of complementary services and technologies that expand the capabilities of the modern research professional. WCG delivers transformational solutions that stimulate growth, foster compliance, and maximize efficiency for those who perform clinical trials.

WCG is proud to serve the individuals on the frontlines of science and medicine, and the organizations that strive to develop new products and therapies to improve the quality of human health. It is our role to empower them to accelerate advancement, while ensuring that the risks of progress never outweigh the value of human life.

For more information, please visit www.wcgclinical.com.

Download the Press Release
[wpdm_package id=’2395′]